Literature DB >> 33311450

TGIF2 promotes the progression of lung adenocarcinoma by bridging EGFR/RAS/ERK signaling to cancer cell stemness.

Renle Du1, Wenzhi Shen2, Yi Liu1, Wenjuan Gao1, Wei Zhou1, Jun Li1, Shuangtao Zhao1, Chong Chen3, Yanan Chen1,4,5, Yanhua Liu1,4,5, Peiqing Sun6, Rong Xiang1,4,5, Yi Shi7,8,9, Yunping Luo10.   

Abstract

TGF-β-induced factor homeobox 2 (TGIF2) is a transcription regulator that plays essential roles in the regulation of development and cell fate decisions. Aberrant expression of TGIF family proteins has been observed in several cancers, including ovarian, esophageal, and colorectal cancers. Here, we report that TGIF2 mediates the EGFR-RAS-ERK signaling pathway to enhance the stemness of lung adenocarcinoma (LUAD) cells and, therefore, promote the progression and metastasis of LUAD. We found that high TGIF2 expression was closely correlated with tumor growth, lymph node metastasis, and survival of patients with LUAD. Mice bearing TGIF2-silenced H1299 xenografts developed smaller tumors and fewer lung metastases. Importantly, silencing TGIF2 decreased the cancer stem cell (CSC)-like properties in A549 and H1299 cells. Furthermore, we identified that TGIF2 binding to the OCT4 promoter promotes its expression. In both LUAD cells and in vivo LUAD mouse models, we revealed that EGFR-RAS-ERK signaling phosphorylated TGIF2 and increased its stability, which was important for TGIF2-promoted LUAD stemness since phosphorylation-deficient TGIF2 mutants lost these functions. Thus, our study revealed that an important factor, TGIF2, bridges EGFR signaling to the CSC characteristics of LUAD cells, which can be utilized as an effective target for LUAD therapy.

Year:  2019        PMID: 33311450     DOI: 10.1038/s41392-019-0098-x

Source DB:  PubMed          Journal:  Signal Transduct Target Ther        ISSN: 2059-3635


  45 in total

Review 1.  Opinion: the origin of the cancer stem cell: current controversies and new insights.

Authors:  Rolf Bjerkvig; Berit B Tysnes; Karen S Aboody; Joseph Najbauer; A J A Terzis
Journal:  Nat Rev Cancer       Date:  2005-11       Impact factor: 60.716

2.  The Gata5 target, TGIF2, defines the pancreatic region by modulating BMP signals within the endoderm.

Authors:  Francesca M Spagnoli; Ali H Brivanlou
Journal:  Development       Date:  2007-12-19       Impact factor: 6.868

Review 3.  Stem cells, cancer, and cancer stem cells.

Authors:  T Reya; S J Morrison; M F Clarke; I L Weissman
Journal:  Nature       Date:  2001-11-01       Impact factor: 49.962

4.  Cancer stem cells: the challenges ahead.

Authors:  Jan Paul Medema
Journal:  Nat Cell Biol       Date:  2013-04       Impact factor: 28.824

5.  TGIF2 interacts with histone deacetylase 1 and represses transcription.

Authors:  T A Melhuish; C M Gallo; D Wotton
Journal:  J Biol Chem       Date:  2001-06-26       Impact factor: 5.157

Review 6.  EMT, CSCs, and drug resistance: the mechanistic link and clinical implications.

Authors:  Tsukasa Shibue; Robert A Weinberg
Journal:  Nat Rev Clin Oncol       Date:  2017-04-11       Impact factor: 66.675

Review 7.  Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits.

Authors:  Kornelia Polyak; Robert A Weinberg
Journal:  Nat Rev Cancer       Date:  2009-03-05       Impact factor: 60.716

8.  The epithelial-mesenchymal transition generates cells with properties of stem cells.

Authors:  Sendurai A Mani; Wenjun Guo; Mai-Jing Liao; Elinor Ng Eaton; Ayyakkannu Ayyanan; Alicia Y Zhou; Mary Brooks; Ferenc Reinhard; Cheng Cheng Zhang; Michail Shipitsin; Lauren L Campbell; Kornelia Polyak; Cathrin Brisken; Jing Yang; Robert A Weinberg
Journal:  Cell       Date:  2008-05-16       Impact factor: 41.582

9.  Cancer statistics in China, 2015.

Authors:  Wanqing Chen; Rongshou Zheng; Peter D Baade; Siwei Zhang; Hongmei Zeng; Freddie Bray; Ahmedin Jemal; Xue Qin Yu; Jie He
Journal:  CA Cancer J Clin       Date:  2016-01-25       Impact factor: 508.702

10.  Cell state plasticity, stem cells, EMT, and the generation of intra-tumoral heterogeneity.

Authors:  Geoffrey M Wahl; Benjamin T Spike
Journal:  NPJ Breast Cancer       Date:  2017-04-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.